Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|November 7, 2016
18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimenMatthew Scarpelli, Justine Yang Bruce, Lakeesha Carmichael, et al.
Investigational New Drugs|January 13, 2011
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation designAmye Tevaarwerk, George Wilding, Jens Eickhoff, et al.
Journal for Immunotherapy of Cancer|March 15, 2018
Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccineEllen Wargowski, Laura E Johnson, Jens C Eickhoff, et al.
Investigational New Drugs|December 22, 2010
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malateJustine Yang Bruce, Jens Eickhoff, Roberto Pili, et al.
Investigational New Drugs|March 1, 2016
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancerChristos E Kyriakopoulos, Elisabeth I Heath, Jens C Eickhoff, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2012
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancerDouglas G McNeel, Heath A Smith, Jens C Eickhoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignanciesAmye J Tevaarwerk, Kyle D Holen, Dona B Alberti, et al.
American Journal of Nuclear Medicine and Molecular Imaging|May 15, 2015
Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patientsSaima Muzahir, Robert Jeraj, Glenn Liu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 9, 2016
Utilization and evaluation of noncore chemotherapy regimens within an academic medical centerJason R Jared, Mary S Mably, Rory Makielski, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancerDouglas G McNeel, Hamid Emamekhoo, Jens C Eickhoff, et al.
Pageof 13